Scarica l'app Stockscreener
6.195
8.12%
0.465
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
Lost Money on Verve Therapeutics, Inc.(VERV)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Transcript : Verve Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 09 - marketscreener.com
Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average - Yahoo Finance
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - Yahoo Finance
BNP Paribas Financial Markets Purchases Shares of 8,876 Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by ProShare Advisors LLC - Defense World
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Verve Therapeutics Grants Equity Awards to New Employees as Part of Inducement Stock Incentive Plan - Nasdaq
Latest Employee Stock Grants: Verve Therapeutics Issues 87,000 Shares Worth of Equity Awards - Stock Titan
Bank of America Corp DE Reduces Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Ameriprise Financial Inc. - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Deutsche Bank AG - Defense World
Nuveen Asset Management LLC Sells 355,953 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
37,984 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Acquired by D. E. Shaw & Co. Inc. - Defense World
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVERV - ACCESS Newswire
Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV) - The Globe and Mail
Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Verve Therapeutics (NASDAQ:VERV) Upgraded at Wall Street Zen - Defense World
Northern Trust Corp Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Transcript : Verve Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
Analysts Offer Predictions for VERV FY2026 Earnings - Defense World
3 Top Genomics Stocks to Add to Your Portfolio in 2025 - Yahoo Finance
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st
Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance
Cantor Fitzgerald Issues Positive Outlook for VERV Earnings - Defense World
Price T Rowe Associates Inc. MD Lowers Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $25.75 - Defense World
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail
Dimensional Fund Advisors LP Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics: Q1 Earnings Snapshot - CT Insider
Verve Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
Verve Therapeutics (VERV) Beats Q1 EPS Estimates, Reports Signif - GuruFocus
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances - GuruFocus
Verve Therapeutics, Inc. SEC 10-Q Report - TradingView
Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances Clinical Trials | VERV Stock News - GuruFocus
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Wednesday - Defense World
Stifel Financial Corp Purchases 9,736 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Tower Research Capital LLC TRC Lowers Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street - AOL.com
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):